Coupling of Neural Activity and Retinal Blood Flow in Diabetes
The prevalence of diabetes is increasing and the management of the disease is nowadays considered a major challenge. Affected patients have increased mortality and morbidity as well as a significant drop in the quality of life. The complications of diabetes can be classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular (e.g. cardiovascular or cerebrovascular).
Several large-scale epidemiologic studies indicating that wider retinal venous caliber is strongly associated with the fasting glucose level as well as with diabetes. Another retinal vascular abnormality that is associated with diabetes is an abnormal retinal vascular response to flicker stimulation. Retinal vessel dilatation in response to stimulation with diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means that increased activity of neurons is associated with an increased retinal metabolism. This leads to a release of endogenous vasodilator substances and increased blood flow. However, previous studies were limited by the fact that retinal vessel diameters and blood flow were not measured simultaneously.
The present study aims to investigate whether the response of retinal vessel diameters and blood flow velocities to flicker stimulation is altered in patients with diabetes. Both parameters will be measured in real time using Fourier Domain Doppler OCT.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Men and women aged over 18 years, nonsmokers
- Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant
- normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters
- inclusion criterion of patients is type I diabetes with non or mild non-proliferative retinopathy
Exclusion criteria
Any of the following will exclude a healthy subject from the study:
- Regular use of vasoactive drugs
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- History or presence of any ocular pathology
- History or family history of epilepsy
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- Pregnancy
Any of the following will exclude a subject with diabetes from the study:
- Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)
- History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy
- Best corrected visual acuity <0.8
- Previous laser photocoagulation treatment
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- History or family history of epilepsy
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- Pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Diabetic retinopathy
Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
|
|
healthy
healthy control subjects
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Retinal vessel diameters
Periodo de tiempo: 18 months
|
18 months
|
|
Retinal blood flow velocities
Periodo de tiempo: 18 months
|
18 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- OPHT-070111
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .